Volume | 99,826 |
|
|||||
News | - | ||||||
Day High | 3.14 | Low High |
|||||
Day Low | 3.05 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.0788 | 3.05 | 3.14 | 3.14 | 3.12 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,074 | 99,826 | $ 3.09 | $ 308,606 | - | 2.21 - 12.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:57:54 | 2 | $ 3.06 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
263.51M | 83.92M | - | 0 | -30.16M | -0.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NRX Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.03 | 3.26 | 2.7201 | 3.03 | 283,191 | 0.11 | 3.63% |
1 Month | 4.80 | 6.00 | 2.7201 | 4.68 | 472,214 | -1.66 | -34.58% |
3 Months | 3.70 | 7.333 | 2.7201 | 5.11 | 1,503,503 | -0.56 | -15.14% |
6 Months | 2.769 | 7.333 | 2.603 | 4.70 | 1,144,087 | 0.371 | 13.40% |
1 Year | 6.00 | 12.00 | 2.21 | 4.20 | 1,020,217 | -2.86 | -47.67% |
3 Years | 230.10 | 262.40 | 2.21 | 69.34 | 1,606,885 | -226.96 | -98.64% |
5 Years | 230.10 | 262.40 | 2.21 | 69.34 | 1,606,885 | -226.96 | -98.64% |
NRX Pharmaceuticals Description
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |